MedTrace Logo

Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290

NCT02093546 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-01-28

No results posted yet for this study

Summary

This trial assesses blood and tumor samples for the effect of trametinib with or without uprosertib on biomarkers in patients enrolled on trial GOG02290 with endometrial cancer that is persistent or has come back. Biomarkers found in the blood and tissue may be related to the reaction or response to the study drugs.

Conditions

  • Recurrent Endometrial Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood and tumor

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Shannon Westin · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-13
Primary Completion
2020-01-15
Completion
2020-01-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02093546 on ClinicalTrials.gov